Akero Therapeutics, Inc. (AKRO) — Financial statements
Income statement, balance sheet, and cash flow for Akero Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.21 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.21 | |
| Operating Expenses | ||||||
| R&D Expenses | 247↑74.5% | 142↑66.3% | 85↑4.3% | 82↑25.9% | 65 | |
| General & Administrative Expenses | 38↑22.1% | 31↑4.0% | 30↑56.2% | 19↑25.5% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 38↑22.1% | 31↑4.0% | 30↑56.2% | 19↑25.5% | 15 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 285↑65.1% | 173↑50.1% | 115↑14.1% | 101↑25.9% | 80 | |
| Total Costs & Expenses | 285↑65.1% | 173↑50.1% | 115↑14.1% | 101↑25.9% | 80 | |
| Operating Results | ||||||
| Operating Income | -285↓65.1% | -173↓50.1% | -115↓14.1% | -101↓25.9% | -80 | |
| Depreciation & Amortization | 0.02↓37.9% | 0.03↓32.6% | 0.04↑4.9% | 0.04↓80.8% | 0.21 | |
| EBITDA | -247↓66.4% | -149↓33.6% | -111↓10.4% | -101↓27.5% | -79 | |
| EBIT | -247↓66.4% | -149↓33.6% | -111↓10.4% | -101↓27.2% | -79 | |
| Interest & Other Income | ||||||
| Net Interest Income | 33↑58.0% | 21↑576.0% | 3↑2765.1% | 0.11↓88.5% | 0.95 | |
| Interest Income | 38↑57.1% | 24↑526.9% | 4↑3443.1% | 0.11↓88.5% | 0.95 | |
| Interest Expense | 5↑50.6% | 3↑319.4% | 0.74 | 0.00 | 0.00 | |
| Non-Operating Income | -38↓57.1% | -24↓526.9% | -4↓3443.1% | -0.11↑88.5% | -0.95 | |
| Other Income / Expenses | 33↑58.0% | 21↑576.0% | 3↑2765.1% | 0.11↓88.5% | 0.95 | |
| Income Before Tax | -252↓66.1% | -152↓35.5% | -112↓11.2% | -101↓27.2% | -79 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -252↓66.1% | -152↓35.5% | -112↓11.2% | -101↓27.3% | -79 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -252↓66.1% | -152↓35.5% | -112↓11.2% | -101↓27.3% | -79 | |
| Bottom-Line Net Income | -252↓66.1% | -152↓35.5% | -112↓11.2% | -101↓27.2% | -79 | |
| EPS (Basic) | -3.75↓29.8% | -2.89↓0.7% | -2.87↑0.7% | -2.89↓14.7% | -2.52 | |
| EPS (Diluted) | -3.75↓29.8% | -2.89↓0.7% | -2.87↑0.7% | -2.89↓14.7% | -2.52 | |
| Weighted Average Shares | 67↑27.7% | 53↑34.8% | 39↑11.9% | 35↑10.7% | 31 | |
| Weighted Average Diluted Shares | 67↑27.7% | 53↑34.8% | 39↑11.9% | 35↑10.7% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.